

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JIWA BIO-PHARM HOLDINGS LIMITED

積華生物醫藥控股有限公司 *

(Incorporated in Bermuda with limited liability)

(Stock Code: 2327)

RE-DESIGNATION OF CHIEF EXECUTIVE OFFICER

The Board of Directors (the “Board”) of Jiwa Bio-Pharm Holdings Limited (the “Company”, together with its subsidiaries, collectively, the “Group”) announces that Mr. Lau Kin Tung (“Mr. Lau”), a Vice Chairman and Chief Executive Officer of the Company, shall cease to be the Chief Executive Officer with effect from the date of this announcement. Mr. Lau shall remain as Vice Chairman and Executive Director of the company. The Board also announces that Madam Chan Hing Ming (“Madam Chan”), an Executive Director of the Company is being appointed as the Chief Executive Officer of the Company with effect from the date of this announcement.

The Group carried out reorganization as at the beginning of 2011, 昆明積大製藥有限公司 (Kunming Jida Pharmaceutical Company Limited*) (“Kunming Jida”) which equity interest is originally owned as to 70% by the Group has allotted and issued 30% equity interest of the company to the strategic investors, meanwhile, it included 雲南積華醫藥物流有限公司 (Yunnan Jiwa Pharm Logistics Company Limited*) (“Yunnan Jiwa”) and 江蘇積華靈大製藥有限公司 (Jiangsu Jiwa Rintech Pharmaceutical Company Limited*) (“Jiangsu Jiwa”) into the Mainland pharmaceutical business structure, with Kunming Jida as the leading Company. Kunming Jida is now a 49% owned associated company of the Company and Yunnan Jiwa and Jiangsu Jiwa is now the wholly owned subsidiary of Kunming Jida. To cater for business development, reallocation of human resources has also been carried out in the Company. Since then, Madam Chan will focus on the business developments and strategic investment projects of the Group to maximize returns for shareholders. Mr. Lau shall remain as General Managers of Kunming Jida and Jiangsu Jiwa, focus on the development of the pharmaceutical business and be responsible for the strategic plan of the Group.

Madam Chan Hing Ming, aged 70, is one of the founders of the Group. She joined the Group in 1978. Madam Chan has over 29 years of experience in investment, corporate finance and corporate management. Madam Chan has been responsible for the financial management of the Group and assisted in founding Kunming Jida, Jiangsu Jiwa and Yunnan Jiwa.

* For identification purpose only

Madam Chan is the spouse of Mr. Lau Yau Bor, the Chairman of the Group, and the mother of Mr. Lau Kin Tung. Save as disclosed, Madam Chan has no relationship with any other directors, senior management or substantial or controlling shareholders of the Company.

Other than holding the directorship in the Company, Madam Chan is the director and shareholder of MINGS Development Holdings Limited, a company incorporated in the British Virgin Islands, which holds as to 4.66% of the shares of the Company; and the director of Jiwa Pharmaceuticals Limited, Tech-Medi Development Limited, Jiwa International Limited, Jiwa Rintech Holdings Limited, Sino Tech International (Macao Commercial Offshore) Limited, Jiwa Pharm & Chemicals Limited, Base Affirm International Limited and Rise Hill Development Limited, which are subsidiaries of the Company. Save as disclosed, Madam Chan does not hold any other positions within the Group, and save for the Company, Madam Chan has not hold any directorship in any listed company in the last three year.

Madam Chan has entered into a service contract with the Company for an initial period of three years commencing 1 April 2003 and shall continue thereafter for successive terms of one year. Madam Chan is also entitled to a director's emoluments of HK\$70,000 per month. Madam Chan's emoluments are determined with reference to her duties, responsibilities and experience, and to prevailing market conditions.

As at the date of this Announcement, Madam Chan was deemed to be interested in 1,051,572,000 Shares, representing 65.32% interest in the total issued Shares within the meaning of Part XV of the SFO. Of these 1,051,572,000 shares, 75,000,000 shares were owned by MINGS Development Holdings Limited, which is wholly and beneficially owned by Madam Chan; 840,000,000 shares were held by LAUs Holding Co. Ltd, which is wholly and beneficially owned by Lau Yau Bor, the spouse of Chan Hing Ming; 94,860,000 shares were held by Lau Yau Bor as beneficial owner.

Mr. Lau Kin Tung, aged 41, joined the Group in 1992 and has been responsible for the international trading, research and development, sales and marketing of the Group. Mr. Lau holds a Bachelor of Business Administration Degree from the University of Hong Kong (1992), a Master of Business Administration Degree from the University of Manchester (2002), and a Bachelor of Science Degree in Pharmaceutical Studies from the University of Sunderland (2003).

Mr. Lau is the son of Mr. Lau Yau Bor, the Chairman of the Group and Madam Chan Hing Ming, a director. Save as disclosed, Mr. Lau has no relationship with any other directors, senior management or substantial or controlling shareholders of the Company.

Other than holding the directorship in the Company, Mr. Lau is also the director and shareholder of WHYS Holding Co Ltd, a company incorporated in the British Virgin Islands, which holds as to 6.52% of the Shares of the Company; and the director of Yunnan Jiwa Biotech Limited, Jiwa Pharmaceuticals Limited, Tech-Medi Development Limited, Jiwa Development Company Limited,

Jiwa Rintech Holdings Limited, Sino Tech International (Macao Commercial Offshore) Limited, Jiwa Pharm & Chemicals Limited, Base Affirm International Limited and Rise Hill Development Limited, which are subsidiaries of the Company. Save as disclosed, Mr. Lau does not hold any other positions within the Group, and save for the Company, Mr. Lau has not hold any directorship in any listed company in the last three year.

Mr. Lau has entered into a service contract with the Company for an initial period of three years commencing 1 April 2003 and shall continue thereafter for successive terms of one year. Mr. Lau is also entitled to a director's emoluments of HK\$30,000 per month and discretionary bonus. Mr. Lau's emoluments are determined with reference to his duties, responsibilities and experience, and to prevailing market conditions.

As at the Latest Practicable Date, Mr. Lau had interest in 105,000,000 Shares, representing 6.52% interest in the total issued Shares within the meaning of Part XV of the SFO. Those Shares were held by WHYS Holding Co. Ltd, which is wholly and beneficially owned by Mr. Lau.

Other Disclosable Information under Rule 13.51(2)

Save as disclosed above, there are no other matters concerning the re-designations of Madam Chan nor Mr. Lau that need to be brought to the attention of the shareholders of the Company nor any information which is discloseable under any of the requirement set out in Rule 13.51(2)(h) to 13.51(2)(w) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board
Jiwa Bio-Pharm Holdings Limited
Lau Yau Bor
Chairman

Hong Kong, 24 June 2011

As at the date of this announcement, the executive Directors of the Company are Mr. Lau Yau Bor, Madam Chan Hing Ming and Mr. Lau Kin Tung; and the independent non-executive Directors are Mr. Chiu Wai Piu, Mr. Choy Ping Sheung and Mr. Fung Tze Wa.